Merck, Inc.
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6105
- Registration Number
- NCT05093933
- Locations
- 🇨🇦
G A Research Associates ( Site 0652), Moncton, New Brunswick, Canada
🇺🇸South Florida Research Solutions ( Site 0058), Hollywood, Florida, United States
🇺🇸Georgia Arrhythmia Consultants and Research Institute ( Site 0042), Macon, Georgia, United States
A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT05070390
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC ( Site 0001), Knoxville, Tennessee, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale Beach, Florida, United States
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 830
- Registration Number
- NCT05067283
- Locations
- 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 441
- Registration Number
- NCT05064059
- Locations
- 🇨🇳
Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital ( Site 1158), Nanning, Guangxi, China
🇨🇳Wuhan Union Hospital Cancer Center ( Site 1162), Wuhan, Hubei, China
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
- Conditions
- Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT05038800
- Locations
- 🇮🇱
Hadassah Medical Center ( Site 0100), Jerusalem, Israel
🇮🇱Sheba Medical Center-Hemato Oncology ( Site 0101), Ramat Gan, Israel
🇺🇸University of Texas MD Anderson Cancer Center ( Site 0004), Houston, Texas, United States
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT05030506
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital ( Site 0003), Tianjin, Tianjin, China
🇨🇳Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China
🇨🇳Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, Nanjing, Jiangsu, China
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
- Conditions
- Kidney Failure, ChronicEnd-Stage Renal DiseaseEnd-Stage Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 506
- Registration Number
- NCT05027074
- Locations
- 🇺🇸
Academic Medical Research Institute ( Site 0533), Los Angeles, California, United States
🇺🇸Fresenius Kidney Care Newhope Fountain Valley ( Site 0617), Fountain Valley, California, United States
🇺🇸DaVita Crescent Heights Dialysis Center ( Site 0574), Los Angeles, California, United States
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05017012
- Locations
- 🇨🇱
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile
🇨🇱FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile
🇿🇦Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT05008224
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Conditions
- Endometrial NeoplasmsUterine Cervical NeoplasmsSquamous Cell Carcinoma of Head and NeckUrinary Bladder NeoplasmsCholangiocarcinomaEsophageal NeoplasmsOvarian NeoplasmsTriple Negative Breast NeoplasmsHepatocellular CarcinomaGallbladder Neoplasms
- Interventions
- Biological: Pembrolizumab/Vibostolimab Co-Formulation
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 613
- Registration Number
- NCT05007106
- Locations
- 🇺🇸
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States